

# People

## People

### Diversa announces new Executive Vice-President

Diversa Corporation (<http://www.diversa.com>) has announced the appointment of William H. Baum to the position of Executive Vice-President. In his new role, Baum will be responsible for the management of Diversa's chemical products business group, which includes agbiotech and industrial enzymes.

Baum joined Diversa as Vice President (VP) of Sales and Marketing in 1997 and has previously held the position of VP of Global Sales and Marketing with International Speciality Products. Before this he was with Betz Laboratories in a variety of executive management positions, including Executive VP of European operations in Belgium and Managing Director for Germany.

### Blizzard Genomics name new CEO

The genomics and proteomics company Blizzard Genomics (<http://www.blizzardgenomics.com>) has announced the appointment of James V. Adam as Chief Executive Officer, succeeding the company's founder, Martin Blumenfield. Blumenfield will remain with the company as Chief Scientific Officer responsible for research.

Adam, who joined Blizzard Genomics as President in 2001, has 30 years of business experience in companies ranging from major multinational financial services organizations to small biotech, pharmaceutical and Internet companies. He is also Founder of Adam Consulting, a company that aims to help small entrepreneurial businesses achieve success; President of Ican, an Internet provider of infectious disease information to medical professionals and retired Chief Operating Officer and Chief Financial Officer of MGI Pharma, a company that focuses on cancer therapy.

### Changes at BioVision

BioVision AG (<http://www.biovision.de>) has appointed Wolfgang Trefzger as Chief Financial Officer and Rudolf Reiter, previously Director of Project Management,

as Chief Operating Officer (COO). The former COO, Michael Schrader, will now head the technology division as Chief Technology Officer.

Reiter has years of experience in the pharmaceutical industry as a result of his managerial function at Boehringer Mannheim GmbH-Roche Diagnostics GmbH. Trefzger has worked for several companies in medical technology and biotechnology and has years of experience in commercial and financial management.

### Lexicon Genetics appoints Brian P. Zambrowicz

Lexicon Genetics (<http://www.lexgen.com>) has appointed Brian P. Zambrowicz as Executive Vice President of Research. Zambrowicz joined Lexicon in 1996 and was a key player in both the invention of the company's high-throughput gene trapping technology and establishing Lexicon's large-scale *in vivo* target discovery platform. Most recently he was responsible for molecular genetics and genomics based research in his position as Senior Vice President of Genomics.

Before joining Lexicon, Zambrowicz was an NIH postdoctoral fellow at the Fred Hutchinson Cancer Centre in Seattle, where he studied gene trapping and gene targeting technology.

Arthur T. Sands, President and Chief Executive Officer of Lexicon, said: 'Brian's promotion to this new position is a significant step in the evolution of Lexicon's management team as we achieve our science and business goals of discovering breakthrough treatments for human disease.'

## Awards

### William B. Coley award for David Raulet

The Cancer Research Institute's prestigious William B. Coley award has been awarded to David Raulet for his research of natural killer cell receptors and ligands and his outstanding achievement in the fields of basic and tumour immunology.

Raulet is a member of the Scientific Advisory Board for Innate Pharma

(<http://www.innate-pharma.fr>), developer of novel anti-tumour therapies, and joined the board upon its formation in 2000. Raulet's research and development as a specialist in cellular and molecular immunology has led to a greater understanding of the mechanisms employed by the immune system when fighting disease.

Hervé Brailly, CEO of Innate Pharma, said, 'We congratulate David Raulet on this outstanding award. His recent work is a strong endorsement of the concepts behind Innate Pharma and a great encouragement for our continued research.'

Raulet manages the Immunology Department at the University of California, Berkeley, and teaches immunology in the molecular and cellular biology department.

### London Biotechnology Network Entrepreneur awards

Two awards for outstanding contributions to the biotechnology sector were presented at the London Biotechnology Network (LBN) Entrepreneur of the Year Awards, by Lord Sainsbury, Minister for Science and Innovation.

Ken Powell, Chief Executive of Arrow Therapeutics (<http://www.arrowt.co.uk>) received his 'Entrepreneur of the Year' award for being the founder of several start-up companies in London, and a true innovator. As former deputy director of the Wolfson Institute, Powell was responsible for the development of the institutes facilities and infrastructure. Before this he was Head of Biology at the Wellcome Foundation.

Peter Shepherd received his award for 'Young Entrepreneur of the Year' in recognition of his achievements in the pioneering work on the cause of Type 2 diabetes. His research on human-based systems for drug discovery led to the formation of Xcellsyz, where he is Chief Scientific Officer.

Simon Tarpey, Director of LBN, said: 'These awards recognise the tremendous, innovative work of these two individuals. They are both contributing to the fast growing biotechnology sector in London, which is built on the universities' increasing sophistication in commercializing biotechnology research by forming new company spin-outs.'

People was written by  
*Joanne Clough and Joanna Owens*